Literature DB >> 9512919

Selecting an antidepressant for use in a patient with epilepsy. Safety considerations.

S Curran1, K de Pauw.   

Abstract

Depression is a common and disabling condition and is especially disabling for patients who also have epilepsy. Antidepressants, particularly the tricyclic antidepressants are well known to be associated with seizure activity, but this is a very neglected area of research. Most of the data on the proconvulsive effects of antidepressants come from either work in animal models or from research into the effects of antidepressants in overdose. Both of these situations may tell us little about the behaviour of antidepressants in patients with epilepsy. The selective serotonin [5-hydroxytryptamine; 5-HT] reuptake inhibitors have a low seizure propensity, are well tolerated in overdose and have a favourable adverse effect profile, making them suitable as first line treatments for depression in patients with epilepsy. Other antidepressants, e.g. trazodone, moclobemide, mirtazepine, are also likely to have minimal proconvulsive effects, but adverse effects, interactions with other drugs, especially anticonvulsants, or the lack of clinical data may make their use less attractive. Although this review has focused on these clinically important issues it is clear that considerably more research needs to be undertaken on the seizure propensity and clinical efficacy of antidepressants in patients with epilepsy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9512919     DOI: 10.2165/00002018-199818020-00004

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  39 in total

1.  Seizure activity associated with fluoxetine therapy.

Authors:  J J Weber
Journal:  Clin Pharm       Date:  1989-04

2.  Seizures associated with fluoxetine therapy.

Authors:  M R Ware; R B Stewart
Journal:  DICP       Date:  1989-05

Review 3.  The safety of fluoxetine--an update.

Authors:  G L Cooper
Journal:  Br J Psychiatry Suppl       Date:  1988-09

4.  Effect of paroxetine on seizure length during electroconvulsive therapy.

Authors:  S Curran
Journal:  Acta Psychiatr Scand       Date:  1995-09       Impact factor: 6.392

5.  Antiepileptic therapy, folate deficiency, and psychiatric morbidity: a general practice survey.

Authors:  J Edeh; B K Toone
Journal:  Epilepsia       Date:  1985 Sep-Oct       Impact factor: 5.864

6.  ECG lead aVR versus QRS interval in predicting seizures and arrhythmias in acute tricyclic antidepressant toxicity.

Authors:  E L Liebelt; P D Francis; A D Woolf
Journal:  Ann Emerg Med       Date:  1995-08       Impact factor: 5.721

7.  Anticonvulsant effects of intracerebroventricularly administered norepinephrine are potentiated in the presence of monoamine oxidase inhibition in severe seizure genetically epilepsy-prone rats (GEPR-9s).

Authors:  P K Mishra; E H Kahle; A F Bettendorf; J W Dailey; P C Jobe
Journal:  Life Sci       Date:  1993       Impact factor: 5.037

Review 8.  Seizures associated with antidepressants: a review.

Authors:  D L Rosenstein; J C Nelson; S C Jacobs
Journal:  J Clin Psychiatry       Date:  1993-08       Impact factor: 4.384

9.  QRS interval in tricyclic antidepressant overdosage: inaccuracy as a toxicity indicator in emergency settings.

Authors:  G E Foulke; T E Albertson
Journal:  Ann Emerg Med       Date:  1987-02       Impact factor: 5.721

10.  Greater toxicity in overdose of dothiepin than of other tricyclic antidepressants.

Authors:  N A Buckley; A H Dawson; I M Whyte; D A Henry
Journal:  Lancet       Date:  1994-01-15       Impact factor: 79.321

View more
  3 in total

1.  Managing depressive disorders in patients with epilepsy.

Authors:  Madhukar H Trivedi; Ben T Kurian
Journal:  Psychiatry (Edgmont)       Date:  2007-01

2.  Pharmacotherapy of Mood Disorders in Epilepsy: The Role of Newer Psychotropic Drugs.

Authors:  Andres M Kanner; Antoaneta J Balabanov
Journal:  Curr Treat Options Neurol       Date:  2005-07       Impact factor: 3.972

Review 3.  Depression and anxiety in people with epilepsy.

Authors:  Oh-Young Kwon; Sung-Pa Park
Journal:  J Clin Neurol       Date:  2014-07-03       Impact factor: 3.077

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.